# EDGAR Filing Document

**Accession Number:** 0001929281
**File Stem:** 0000000000-23-001639
**Filing Date:** 2023-2
**Character Count:** 3755
**Document Hash:** e4069250180155c14cff338f1aa8ad30
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001639.hdr.sgml**: 20230321

**ACCESSION NUMBER**: 0000000000-23-001639

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230217

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioLIfe Sciences Inc
- **CENTRAL INDEX KEY:** 0001929281
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 542013455
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1130

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 2831 SAINT ROSE PARKWAY
- **STREET 2:** SUITE 200
- **CITY:** HENDERSON
- **STATE:** NV
- **ZIP:** 89052
- **BUSINESS PHONE:** 647-470-2278

**MAIL ADDRESS:**
- **STREET 1:** 2831 SAINT ROSE PARKWAY
- **STREET 2:** SUITE 200
- **CITY:** HENDERSON
- **STATE:** NV
- **ZIP:** 89052

## Text-Extract

```

United States securities and exchange commission logo

                           February 17, 2023

       Justin De Four
       Chairman, CEO and Director
       BioLIfe Sciences, Inc.
       2831 St. Rose Parkway #200
       Henderson, NV 89052

                                                        Re: BioLIfe Sciences
Inc
                                                            Post-Qualification
Amendment No. 2 to Offering Statement on Form 1-A
                                                            Filed February 9,
2023
                                                            File No. 024-11898

       Dear Justin De Four:

                                                        This is to advise you
that we do not intend to review your amendment.

               We will consider qualifying your offering statement at your
request. If a participant in
       your offering is required to clear its compensation arrangements with
FINRA, please have
       FINRA advise us that it has no objections to the compensation
arrangements prior to
       qualification.

               We remind you that the company and its management are
responsible for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
       action by the staff.

                                                        Please contact Daniel
Crawford at 202-551-7767 with any questions.

                           Sincerely,

                           Division of Corporation Finance

                           Office of Life Sciences
       cc:                                              Eric Newlan, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 17, 2023

Justin De Four
Chairman, CEO and Director
BioLife Sciences, Inc.
2831 St. Rose Parkway #200
Henderson, NV 89052

Re: BioLife Sciences Inc

Post-Qualification Amendment No. 2 to Offering Statement on Form 1-A

Filed February 9, 2023

File No. 024-11898

Dear Justin De Four:

This is to advise you that we do not intend to review your amendment.

We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Eric Newlan, Esq.